Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
. Y. T$ w1 Y; c* O0 X$ [3 K" Y5 E( ]
/ D/ T+ G; [. v* m( Y; d3 kSub-category:
4 `% M$ X: q$ T( A0 `& |% b( v6 NMolecular Targets : h7 G" I9 _, t: i v% Z f3 O
* U" D0 r! B3 }7 L- h, D
5 X# ?0 w$ X2 K X1 QCategory:2 x2 @) z2 @& A% S' S) \
Tumor Biology 7 x! M3 D. e6 p) |. ^
0 L- t( b0 ?( |# `' S# W' \( W0 w, @- S4 I9 x' u9 u
Meeting:5 t! ~3 P, f$ y* {# o5 |
2011 ASCO Annual Meeting
. i# g' N3 `* t0 M: G( `* S, L6 [2 k6 L. R- H) I- ~3 R0 L9 Y
8 B3 b8 m" G2 `Session Type and Session Title:; V, ]* N& u* M
Poster Discussion Session, Tumor Biology
4 X2 ?9 h* L6 f1 m( ~& u
$ H, T3 t7 `5 E, D4 ~6 J3 r) |2 B
Abstract No:* B5 I( Z% E( K
10517 ! Q* X5 R+ D- u/ n, N# c* N
# f; e" R2 h6 v, O# F# `/ |
3 J8 I; M3 M+ h( c" T: D/ B$ M) k
Citation:4 R* F/ P8 L; b0 y
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 C* q6 X" D" `3 a& C% K
2 G4 B# u' L V5 i; m. L
1 K+ H: Y8 W1 A* gAuthor(s):8 Y+ q8 J# Q- I4 D0 G2 k6 `4 ~
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 1 Z4 E9 ]3 i" g9 i: ]- u
6 j/ o5 }3 \4 J4 X7 i# U6 j
( s' }0 L/ T8 s
R3 U( d9 x! N" L& X
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.( z) I+ Q S, u9 `3 I" P+ x
- }; B7 Q5 D6 H
Abstract Disclosures
& c9 ?) m5 U7 C; H- D% h6 u) t7 {) R% S9 ^* ?
Abstract:* e+ k9 \* P. k. b0 Q
8 B( f7 |/ P2 I: C" F7 A
* r" v! l+ c0 u/ n" P
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ o# U% f8 z% f0 P- R( g3 ^4 n; y* G; ^" u3 @
; C3 k ~( e/ f" d% s1 H6 h2 p$ R |